Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs10421768
rs10421768
0.010 GeneticVariation BEFREE However, rs10421768 in HAMP showed a borderline statistically significant correlation with lung cancer risk (OR = 2.83, p = 0.05). 30640897

2019

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE The amino acid replacement of arginine by proline at codon 72 of TP53 appears not to be important in determining lung cancer risk in this population. 11097227

2000

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE We investigated the association between genetic variation in the promoter region of MDM2 (c.-5+309G>T, rs2279744:g.G>T) and the coding region of TP53 (c.215G>C, rs1042522:g.G>C, designated Arg72Pro) and the risk of developing lung cancer. 16287156

2006

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Therefore, we hypothesized that the genetic variants in these three genes influence the predisposition of lung cancer (i.e., CCND1 G870A, CDKN2A Ala(148)Thr, TP53 Arg(72)Pro, and 16-bp repeat in intron 3) and that the effect of X-ray on lung cancer risk can be modified by the presence of these genetic variations. 16912209

2006

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE We therefore investigated the combined effects of polymorphisms in TP53 (Arg72Pro) and p21/CDKN1A (Ser31Arg) and smoking on lung cancer risk. 17059853

2007

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE African Americans with Pro-T-A-G-G haplotypes of the combined TP53 polymorphisms TP53_01 (rs1042522), TP53_65 (rs9895829), TP53_66 (rs2909430), TP53_16 (rs1625895), and TP53_11 (rs12951053) had both an increased risk for lung cancer (odds ratio, 2.32; 95% confidence interval, 1.18-4.57) and a worsened lung cancer prognosis (hazards ratio, 2.38; 95% confidence interval, 1.38-4.10) compared with those with Arg-T-A-G-T haplotypes. 17301252

2007

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Despite employing a comprehensive set of statistical tests including those sensitive to the detection of differences in early survival our data provide little evidence to support the tenet that the p53 Arg72Pro polymorphism is a clinically useful prognostic marker for lung cancer. 17400332

2007

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Cox regression analysis showed p53 Arg72Pro heterozygous genotype was overall an independent prognostic factor (Risk ratio of death, 2.2; P = 0.02), suggesting Pro72Pro genotype to be a potential risk factor favoring the development of lung carcinoma and that Arg72Pro genotype is independently associated with a poorer prognosis of lung cancer. 18181044

2008

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. 18336951

2008

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Statistical analyses revealed that polymorphisms and haplotypes in the TP53 gene, including Arg72Pro, were not significantly associated with lung cancer in a Korean population. 18363031

2008

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. 18990748

2008

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE More studies stratified for lung cancer stage-genotyping interaction should be performed to clarify the role of TP53 Arg72Pro polymorphism in the development of lung cancer. 19623649

2009

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE The polymorphic frequency of 10 genetic susceptibility genes and their association with lung cancer were examined in a northern Thai population: CYP1A1 (MspI), CYP1A1 (Ile462Val), CYP2E1 (PstI), CYP2E1 (DraI), GSTM1, GSTT1, MPO (AciI), OGG1 (Ser326Cys), TP53 (Arg72Pro), and MMP1(AluI). 19963114

2009

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Present report evaluated the association of polymorphism in exon 4 Arg72Pro (G>C) of the p53 gene with lung cancer susceptibility using 175 cancer cases and 202 controls from the North Indian population. 23317414

2013

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE We performed a meta-analysis to evaluate the relationship between TP53 Arg72Pro polymorphism and lung cancer susceptibility basing on 15,647 lung cancer patients and 14,391 controls from 36 published literatures. 23595658

2013

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE The updated meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism is a risk factor for lung cancer in the Asian population. 23812725

2013

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE We used real-time PCR method to investigate the genotypic frequencies of rs2602141, rs560191 and rs689647 in 53BP1 and rs1042522 in TP53 in 640 cases of lung cancer and 685 controls. 24316395

2014

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE The variant genotype of TP53 SNP rs1042522 significantly increased lung cancer risk in the total population (OR: 1.57, 95% CI: 1.11-2.21), but there was no evidence of heterogeneity among individuals with different lifestyle factors. 24369748

2013

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE We conclude that not Pro47Ser SNP but Arg72Pro SNP is involved in susceptibility to developing lung cancer, at least in Bangladeshi population. 25034526

2014

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE Twenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence. 28827732

2017

dbSNP: rs1042522
rs1042522
0.100 GeneticVariation BEFREE TP53 p.R72P genotype is a marker of poor prognosis in lung cancer. 29286914

2018

dbSNP: rs1042711
rs1042711
0.010 GeneticVariation BEFREE Genetic model analysis shows that rs1042711 and rs1560642 were associated with increased risk of lung cancer; whereas rs7025417, rs5756523, and rs2284033 were associated with decreased disease risk (p < 0.05). 31685439

2019

dbSNP: rs1043973338
rs1043973338
0.010 GeneticVariation BEFREE Two IL1A SNPs (C-889T and Ala(114)Ser) were also related to lung cancer (OR, 1.18-1.22), although FPRPs were higher. 17596594

2007

dbSNP: rs1043994
rs1043994
0.010 GeneticVariation BEFREE In conclusion, the rs3815188 variant and rs1043994 variant of the Notch3 gene is associated with lung cancer risk in patients of Turkish origin. 30806291

2019

dbSNP: rs1044396
rs1044396
0.010 GeneticVariation BEFREE Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer. 31402126

2020